Posted On: 12/05/2012 2:35:03 AM
Post# of 28540
COPENHAGEN, Dec 5 (Reuters) - Danish biotech company Genmab A/S
said on Wednesday:
* Has entered into duobody platform collaboration with Japan's
Kyowa Hakko Kirin
* Collaboration is to create bispecific antibodies using
Genmab's DuoBody technology
* If successful, the parties may decide to enter into a license
agreement to develop a new DuoBody product
* The financial terms of the agreement have not been disclosed,
deal will not have a material impact on Genmab's 2012 financial
guidance
said on Wednesday:
* Has entered into duobody platform collaboration with Japan's
Kyowa Hakko Kirin
* Collaboration is to create bispecific antibodies using
Genmab's DuoBody technology
* If successful, the parties may decide to enter into a license
agreement to develop a new DuoBody product
* The financial terms of the agreement have not been disclosed,
deal will not have a material impact on Genmab's 2012 financial
guidance
(0)
(0)
I test new features, including the new app!
